Technical Analysis for SRZN - Surrozen, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -5.91% | |
| Lizard Bullish | Bullish Day Trade Setup | -5.91% | |
| Doji - Bullish? | Reversal | -5.91% | |
| Multiple of Ten Bullish | Other | -5.91% | |
| 20 DMA Support | Bullish | -5.94% | |
| Multiple of Ten Bullish | Other | -5.94% | |
| Gapped Down | Weakness | -5.94% |
| Alert | Time |
|---|---|
| 20 DMA Support | 1 day ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Surrozen, Inc., a biopharmaceutical company, develops targeted regenerative antibodies to repair a range of tissues and organs damaged by serious disease, and to improve organ function. The company provides antibody platforms that functions as Wnt and R-spondin mimetics in stimulating cell and organ-specific tissue regeneration. Its programs include SZN-043, a liver-specific R-spondin-mimetic to stimulate hepatocyte regeneration in acute and chronic liver disease; and SZN-1326, an intestine-specific Wnt-mimetic to repair diseased epithelial tissue and address an unmet need in patients with inflammatory bowel disease. Surrozen, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Antibodies Antibody Inflammatory Bowel Disease Glycoproteins Organs Senescence Liver Gastrointestinal Tract
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Antibodies Antibody Inflammatory Bowel Disease Glycoproteins Organs Senescence Liver Gastrointestinal Tract
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.19 |
| 52 Week Low | 4.5 |
| Average Volume | 18,449 |
| 200-Day Moving Average | 9.12 |
| 50-Day Moving Average | 11.14 |
| 20-Day Moving Average | 9.82 |
| 10-Day Moving Average | 10.16 |
| Average True Range | 0.91 |
| RSI (14) | 42.20 |
| ADX | 16.74 |
| +DI | 17.13 |
| -DI | 15.35 |
| Chandelier Exit (Long, 3 ATRs) | 8.28 |
| Chandelier Exit (Short, 3 ATRs) | 10.86 |
| Upper Bollinger Bands | 11.00 |
| Lower Bollinger Band | 8.65 |
| Percent B (%b) | 0.38 |
| BandWidth | 23.94 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.24 |
| MACD Histogram | 0.077 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.51 | ||||
| Resistance 3 (R3) | 10.53 | 10.24 | 10.35 | ||
| Resistance 2 (R2) | 10.24 | 9.99 | 10.22 | 10.30 | |
| Resistance 1 (R1) | 9.89 | 9.84 | 9.74 | 9.87 | 10.24 |
| Pivot Point | 9.60 | 9.60 | 9.52 | 9.58 | 9.60 |
| Support 1 (S1) | 9.25 | 9.35 | 9.11 | 9.23 | 8.86 |
| Support 2 (S2) | 8.96 | 9.20 | 8.95 | 8.80 | |
| Support 3 (S3) | 8.61 | 8.96 | 8.75 | ||
| Support 4 (S4) | 8.59 |
